Skip to main content
SpringerLink
Log in

Short-Term Chloral Hydrate Administration and Cancer in Humans

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Objective: Chloral hydrate, used as a hypnosedative in adults and children, has been shown to be genotoxic and carcinogenic in animal studies. We investigated the potential causal association between chloral hydrate exposure and cancer risk in humans.

Methods: Cancer incidence was previously determined via biennial screening analyses of the 215 most commonly used drugs between 1976 and 1998 for a cohort of 143 574 outpatients at Kaiser Permanente who had prescriptions filled between 1969 and 1973. Among users of chloral hydrate, statistically significant elevations in standardised morbidity ratios were observed during various years for cancer at five anatomical sites, including the lung, stomach, prostate, skin melanoma and mouth floor. In this analysis, these associations were investigated using: (i) a dose-response analysis among exposed subjects; and (ii) a two-stage design with exposed and non-exposed persons.

Results: There was evidence of an increasing risk of prostate cancer with increasing number of dispensings of chloral hydrate, which persisted after controlling for benign prostatic hypertrophy, vasectomy and obesity; however, the trend was not statistically significant. There was no evidence of a dose-response relationship between chloral hydrate and risk of any of the other four cancers. In the two-stage design, analyses comparing exposed and unexposed subjects showed no increased risk of cancer after controlling for confounding variables; however, the data were suggestive for prostate cancer, where the increased risk associated with chloral hydrate exposure after adjustment for confounding variables persisted. No dose-response relationship was seen for any of the other four cancer sites.

Conclusions: To our knowledge, this is the first study to examine the relationship between chloral hydrate exposure and cancer risk in humans. There was no persuasive evidence to support a causal relationship between chloral hydrate exposure in humans and the development of cancer. However, statistical power was low for weak associations, particularly for some of the individual cancer sites. Although animal data using much higher doses of chloral hydrate have demonstrated its genotoxicity and carcinogenicity, the effects of chloral hydrate in humans are still uncertain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Graham SR, Day RO, Lee R, et al. Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust 1988; 149: 686–8

    PubMed  CAS  Google Scholar 

  2. Smith MT. Chloral hydrate warning [letter]. Science 1990; 250: 359

    Article  PubMed  CAS  Google Scholar 

  3. Steinberg AD. Should chloral hydrate be banned? Pediatrics 1993; 92: 442–6

    PubMed  CAS  Google Scholar 

  4. Leuschner J, Beuscher N. Studies on the mutagenic and carcinogenic potential of chloral hydrate. Arzneimittel Forschung 1998; 48: 961–8

    PubMed  CAS  Google Scholar 

  5. Ludwigs U, Divino Filho J, Magnusson A, et al. Suicidal chloral hydrate poisoning. J Toxicol Clin Toxicol 1996; 34: 97–9

    Article  PubMed  CAS  Google Scholar 

  6. Harrington-Brock K, Doerr CL, Moore MM. Mutagenicity of three disinfection by-products: di- and trichloroacetic acid and chloral hydrate in L5178Y/TK +/− (−) 3.7.2C mouse lymphoma cells. Mutat Res 1998; 413: 265–76

    Article  PubMed  CAS  Google Scholar 

  7. IARC. Chloral and chloral hydrate. IARC Monogr Eval Carcinog Risk Chem Hum 1995; 63: 245

  8. Salmon AG, Kizer KW, Zeise L, et al. Potential carcinogenicity of chloral hydrate: a review. J Toxicol Clin Toxicol 1995; 33: 115–21

    Article  PubMed  CAS  Google Scholar 

  9. Allen JW, Liang JC, Carrano AV, et al. Review of literature on chemical-induced aneuploidy in mammalian male germ cells. Mutat Res 1986; 167: 123–37

    Article  PubMed  CAS  Google Scholar 

  10. Eichenlaub-Ritter U, Betzendahl I. Chloral hydrate induced spindle aberrations, metaphase I arrest and aneuploidy in mouse oocytes. Mutagenesis 1995; 10: 477–86

    Article  PubMed  CAS  Google Scholar 

  11. Faust JB. Evidence on the carcinogenicity of chloral hydrate (2003 update). Sacramento (CA): Reproductive and Cancer Hazard Assessment Section, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, 2003: 1–29

    Google Scholar 

  12. Steinberg AD, DeSesso JM. Have animal data been used inappropriately to estimate risks to humans from environmental trichloroethylene? Regul Toxicol Pharmacol 1993; 18: 137–53

    Article  PubMed  CAS  Google Scholar 

  13. IARC. Trichloroethylene. IARC Monogr Eval Carcinog Risk Chem Hum 1995; 63: 75

  14. Roe FJ, Salaman MH. Further studies on incomplete carcinogenesis: triethylene melamine (T.E.M.), 1,2-benzanthracene and beta-propiolactone, as initiators of skin tumour formation in the mouse. Br J Cancer 1955; 9: 177–203

    Article  PubMed  CAS  Google Scholar 

  15. Rijhsinghani KS, Abrahams C, Swerdlow MA, et al. Induction of neoplastic lesions in the livers of C57BL × C3HF1 mice by chloral hydrate. Cancer Detect Prev 1986; 9: 279–88

    PubMed  CAS  Google Scholar 

  16. Daniel FB, DeAngelo AB, Stober JA, et al. Hepatocarcinogenicity of chloral hydrate, 2-chloroacetaldehyde, and dichloroacetic acid in the male B6C3F1 mouse. Fundam Appl Toxicol 1992; 19: 159–68

    Article  PubMed  CAS  Google Scholar 

  17. Beland FA. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0): administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 1999 Aug; (59): 1–66, A1-E7

    PubMed  Google Scholar 

  18. George MH, Moore T, Kilburn S, et al. Carcinogenicity of chloral hydrate administered in drinking water to the male F344/N rat and male B6C3F1 mouse. Toxicol Pathol 2000; 28: 610–8

    Article  PubMed  CAS  Google Scholar 

  19. NTP. Toxicology and carcinogenesis studies of chloral hydrate (CAS No. 302-17-0) in male (ad libitum and dietary controlled) B6C3F1 mice (Gavage study), Research Triangle Park (NC): National Institutes of Health, National Toxicology Program; 2002b NTP Technical Report Series No. 503: USDHHS, PHS

  20. Seng JE, Agrawal N, Horsley ET, et al. Toxicokinetics of chloral hydrate in ad libitum-fed, dietary-controlled, and calorically restricted male B6C3F1 mice following short-term exposure. Toxicol Appl Pharmacol 2003; 193: 281–92

    Article  PubMed  CAS  Google Scholar 

  21. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980; 65: 723–33

    PubMed  CAS  Google Scholar 

  22. Friedman GD, Ury HK. Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst 1983; 71: 1165–75

    PubMed  CAS  Google Scholar 

  23. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989; 49: 5736–47

    PubMed  CAS  Google Scholar 

  24. White JE. A two stage design for the study of the relationship between a rare exposure and a rare disease. Am J Epidemiol 1982; 115: 119–28

    PubMed  CAS  Google Scholar 

  25. Weinberg CR, Wacholder S. The design and analysis of case-control studies with biased sampling. Biometrics 1990; 46: 963–75

    Article  PubMed  CAS  Google Scholar 

  26. Chloral hydrate: US Environmental Protection Agency Integrated Risk Information Systems (IRIS) [online]. Available from URL: http://www.epa.gov/iris/subst/0304.htm [Accessed 2001 Jan 2]

  27. Leakey JE, Seng JE, Latendresse JR, et al. Dietary controlled carcinogenicity study of chloral hydrate in male B6C3F1 mice. Toxicol Appl Pharmacol 2003; 193: 266–80

    Article  PubMed  CAS  Google Scholar 

  28. Goodman LS, Gilman A. The pharmacological basis of therapeutics. New York (NY): The Macmillan Co, 1985

    Google Scholar 

  29. Bull RJ. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect 2000; 108: 241–59

    Article  PubMed  CAS  Google Scholar 

  30. Laughter AR, Dunn CS, Swanson CL, et al. Role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology 2004; 203: 83–98

    Article  PubMed  CAS  Google Scholar 

  31. Walgren JL, Jollow DJ, McMillan JM. Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates. Toxicology 2004; 197: 189–97

    Article  PubMed  CAS  Google Scholar 

  32. Austin EW, Okita JR, Okita RT, et al. Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation. Toxicology 1995; 97: 59–69

    Article  PubMed  CAS  Google Scholar 

  33. Stephen RL, Gustafsson MC, Jarvis M, et al. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 2004; 64: 3162–70

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was approved by the Kaiser Permanente Institutional Review Board and supported by Grant #R35 CA49761 from the National Cancer Institute. The authors have no conflicts of interest.

The authors would like to thank Dr Kristin Cobb for her advice and expertise in developing the two-stage design.

Author information

Authors and Affiliations

  1. Division of Epidemiology, Department of Health Research & Policy, Stanford University School of Medicine, Stanford, California, USA

    Tmirah Haselkorn, Alice S. Whittemore & Gary D. Friedman

  2. Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, California, 94612, USA

    Natalia Udaltsova & Gary D. Friedman

Authors
  1. Tmirah Haselkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alice S. Whittemore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalia Udaltsova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gary D. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tmirah Haselkorn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haselkorn, T., Whittemore, A.S., Udaltsova, N. et al. Short-Term Chloral Hydrate Administration and Cancer in Humans. Drug-Safety 29, 67–77 (2006). https://doi.org/10.2165/00002018-200629010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629010-00005

Keywords

Search

Navigation